Determinants of survival for native American adults with HIV infection

AIDS Patient Care and STDs

Volumn 20, Issue 8, 2006, Pages 586-594

  Gorgos, Linda ^a,b   Avery, Erica ^a   Bletzer, Keith ^a   Wilson, Charlton ^a  

^a Whiteriver US Pub Hlth Serv Hosp   (United States)

^b INDIAN HEALTH SERVICE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AMERICAN INDIAN; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; RETROSPECTIVE STUDY; SURVIVAL; URBAN AREA; HEALTH CARE DELIVERY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; STATISTICS; SURVIVAL RATE; UNITED STATES;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; INDIANS, NORTH AMERICAN; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SOUTHWESTERN UNITED STATES; SURVIVAL RATE;

EID: 33748866303     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.586     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. HIV/A1DS Surveillance Report, Vol. 15. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2003.
2. Division of Program Statistics, Office of Program Support, Office of Public Health, Indian Health Service, U.S. Department of Health and Human Services. Trends in Indian Health 2000-2001. U.S. Department of Health and Human Services, 2004.
3. Kelly JJ, Chu SY, Diaz T, Leary LS, Buehler JW. Race/ethnicity misclassification of persons reported with AIDS. The AIDS Mortality Project Group and The Supplement to HIV/AIDS Surveillance Project Group. Ethn Health. 1996;1:87-94.
4. Lieb L, Conway G, Hedderman M, Yao J, Kerndt P. Racial Misclassification of American Indians with AIDS in Los Angeles County. J Acquir Immune Defic Syndr 1992;5:1137-1140.
5. Bertolli J, McNaghten AD, Campsmith M, et al. Surveillance Systems Monitoring HIV/AIDS and AIDS Risk Behaviors Among American Indians and Alaska Natives. AIDS Educ Prev 2004;16:218-237.
6. Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000;355:1158-1159.
7. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-1199.
8. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-129.
9. Fordyce EJ, Singh TP, Nash D, Gallagher B, Forlenza S. Survival rates in NYC in the era of combination ART. J Acquir Immune Defic Syndr 2002;30:111-118.
10. Jaggy C, von Overbeck J, Ledergerber B, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003;362:877-878.
11. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: The EuroSIDA study. Lancet 2000;356:291-296.
12. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22-29.
13. Mocroft A, Youle M, Morcinek J, et al. Survival after diagnosis of AIDS: A prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. BMJ 1997;314:409-413.
14. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
15. Forrest DM, Seminari E, Hogg RS, et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 1998;27:1379-1385.
16. Gulick RMMJ, Havlir D, Eron JJ, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
17. Hammer SMSK, Hughes MD, Grimes JM, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
18. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002;346:1373-1382.
19. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR 1992;41(RR-17):1-19.
20. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, March 23, 2004.
21. Sievers M. Disseminated coccidioidomycosis among southwestern American Indians. Am Rev Resp Dis 1974;109:602-612.
22. Sievers M. Coccidiomycosis among Southwestern American Indians. Am Rev Resp Dis 1964;90:920-926.
23. Aronson J, Saylor R, Parr E. Relationship of coccidiomycosis to calcified pulmonary nodules. Arch Pathol 1942;34:31-48.
24. Ampel N. Coccidioidomycosis among persons with human immunodeficiency virus infection in the era of highly active antiretroviral therapy (HAART). Semin Respir Infect 2001;16:257-262.
25. Woods CWMC, Plikaytis BD, Rosenstein NE, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: Incidence, risk factors, and prevention. J Infect Dis 2000;181:1428-1434.
26. Singh VR SD, Lawerence J, Kelly PC, Thomas AR, Spitz B, Sarosi GA. Coccidioidomycosis in patients infected with human immunodeficiency virus: Review of 91 cases at a single institution. Clin Infect Dis 1996;23:563-568.
27. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999;13:1933-1942.
28. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: The EuroSIDA study. Lancet 2000;356:291-296.
29. Schneider S, Gange SJ, Williams C, et al. Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS 2005;19:2009-2018.
30. Duran B, Bulterys M, Iralu J, Graham Ahmed Edwards CM, Edwards A, Harrison M. American Indians with HIV/AIDS: Health and social service needs, barriers to care, and satisfaction with services among a Western tribe. Am Indian Alsk Native Ment Health Res 2000;9:22-35.
31. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999;13:1687-1695.
32. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. Am J Epidemiol 2000;152:178-185.
33. Craib KJ, Strathdee SA, Hogg RS, et al. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: A predictor of long-term mortality in HIV infection. J Infect Dis 1997;176:798-800.
34. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-2577.
35. Palella FJ, Jr., Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-626.